[Cellular beta-adrenergic receptor complex in patients with heart failure and its changes during digoxin therapy]

Area of Science:

• Cardiology
• Molecular Biology
• Pharmacology

Background:

• Circulatory failure, particularly dilated cardiomyopathy, involves complex cellular signaling pathways.
• Beta-adrenergic receptors play a crucial role in regulating cardiac function through hormonal signal transmission.
• Understanding cellular abnormalities is key to developing effective treatments for heart failure.

Purpose of the Study:

• To investigate the role of cellular beta-adrenoreceptor complex desensitization in patients with circulatory failure.
• To evaluate the effects of digoxin therapy on beta-adrenoreceptor density and adenylate cyclase activity.
• To explore the mechanisms underlying refractoriness to treatment in severe heart failure.

Main Methods:

• Examination of patients with dilated cardiomyopathy, coronary heart disease with cardiosclerosis, and rheumatic heart disease.
• Assessment of beta-adrenoreceptor density and adenylate cyclase activity in cardiac tissue.
• Analysis of clinical and hemodynamic effects of digoxin therapy and plasma catecholamine levels.

Main Results:

• Patients with circulatory failure exhibited decreased beta-adrenoreceptor density, correlating with cardiac decompensation.
• Digoxin therapy initially decreased then increased beta-adrenoreceptor density and enhanced adenylate cyclase activity.
• Some patients with severe heart failure showed no improvement with digoxin, indicating cellular-level abnormalities in beta-adrenergic regulation.

Conclusions:

• Desensitization of the cellular beta-adrenoreceptor complex contributes to circulatory failure, especially in dilated cardiomyopathy.
• Abnormalities in beta-adrenergic regulation are implicated in treatment refractoriness at the cellular level.
• Targeting the catalytic subunit of adenylate cyclase with specific drugs may offer therapeutic benefits in refractory heart failure.